Valuation Novo Nordisk A/S

Equities

Market Closed - Nasdaq Copenhagen Other stock markets 08:50:00 13/09/2024 pm IST			5-day change	1st Jan Change
918.50 ^DKK	+0.47%		+4.20%	+31.57%

13/09	Eli Lilly invests $1.8 billion in Ireland sites to scale up Alzheimer's, obesity drug production	RE
12/09	NOVO NORDISK : Deutsche Bank keeps its Buy rating	ZD

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Capitalization ¹	9,09,347	9,86,612	16,74,992	21,18,803	31,12,331	40,71,846	-	-
Change	-	8.5%	69.77%	26.5%	46.89%	30.83%	-	-
Enterprise Value (EV) ¹	8,98,355	9,84,211	16,84,152	21,21,013	31,09,107	40,85,952	40,62,780	40,30,403
Change	-	9.56%	71.12%	25.94%	46.59%	31.42%	-0.57%	-0.8%
P/E ratio	23.6x	23.7x	35.4x	38.4x	37.5x	40.4x	31.8x	26.7x
PBR	15.8x	15.8x	24x	25.6x	29.4x	28.3x	21x	16.3x
PEG	-	2.38x	2.3x	2.2x	0.7x	1.8x	1.2x	1.4x
Capitalization / Revenue	7.45x	7.77x	11.9x	12x	13.4x	14x	11.7x	10x
EV / Revenue	7.36x	7.75x	12x	12x	13.4x	14.1x	11.6x	9.93x
EV / EBITDA	15.5x	16.4x	26x	25.8x	27.8x	28.7x	23x	19.4x
EV / EBIT	17.1x	18.2x	28.7x	28.4x	30.3x	31.8x	25.2x	21.2x
EV / FCF	26.1x	34.5x	57.4x	37x	45.5x	54.9x	43.1x	34.1x
FCF Yield	3.83%	2.9%	1.74%	2.7%	2.2%	1.82%	2.32%	2.93%
Dividend per Share ²	4.175	4.55	5.2	6.2	9.4	11.4	15.03	17.6
Rate of return	2.16%	2.13%	1.41%	1.32%	1.35%	1.24%	1.64%	1.92%
EPS ²	8.19	9.005	10.37	12.22	18.62	22.71	28.89	34.4
Distribution rate	51%	50.5%	50.1%	50.7%	50.5%	50.2%	52%	51.2%
Net sales ¹	1,22,021	1,26,946	1,40,800	1,76,954	2,32,261	2,90,081	3,48,988	4,05,888
EBITDA ¹	58,144	59,879	64,669	82,171	1,11,987	1,42,456	1,76,414	2,07,955
EBIT ¹	52,483	54,126	58,644	74,809	1,02,574	1,28,373	1,61,428	1,89,856
Net income ¹	38,951	42,138	47,757	55,525	83,683	1,01,797	1,27,816	1,49,148
Net Debt ¹	-10,992	-2,401	9,160	2,210	-3,224	14,105	-9,067	-41,443
Reference price ²	193.32	213.32	367.50	469.00	698.10	918.50	918.50	918.50
Nbr of stocks (in thousands)	47,03,720	46,24,923	45,57,801	45,17,704	44,58,288	44,33,148	-	-
Announcement Date	05/02/20	03/02/21	02/02/22	01/02/23	31/01/24	-	-	-

¹DKK in Million²DKK

Estimates

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E ratio	EV / Sales	EV / EBITDA	Yield (Y)	Capi. ($)
NOVO NORDISK A/S	40.44x	14.09x	28.68x	+1.24%	605B
ELI LILLY AND COMPANY	59.56x	18.45x	44.86x	+0.56%	832B
JOHNSON & JOHNSON	22.5x	4.58x	12.96x	+2.83%	398B
ABBVIE INC.	37.8x	7.16x	15.47x	+3.21%	343B
MERCK & CO., INC.	15.45x	4.91x	11.25x	+2.65%	294B
ROCHE HOLDING AG	15.86x	3.76x	9.85x	+3.71%	252B
ASTRAZENECA PLC	28.09x	5.05x	14.99x	+1.98%	243B
NOVARTIS AG	21.48x	4.95x	12.54x	+3.26%	234B
AMGEN INC.	51.21x	6.89x	12.07x	+2.76%	179B
PFIZER, INC.	21.49x	3.69x	10.08x	+5.69%	166B
Average	31.39x	7.35x	17.27x	+2.79%	354.59B
Weighted average by Cap.	36.39x	9.81x	22.94x	+2.21%